J9340 is terminated (historical record)
Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J9340
15 MG
No published MUE for J9340. CMS keeps some MUE values confidential, so this does not mean there is no daily unit limit.
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Most recent Medicare Part B payment limit · Q2 2025
$245.049per 15 MG
Effective Apr 1, 2025 – Jun 30, 2025 · ASP methodology (per CMS file) · based on Q4 2024 ASP data · coinsurance 20.000%
Not in the latest payment limit file (Q4 2026). Shown for history only.
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $245.049 | 15 MG | 20% | +10.5% | — |
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $221.753 | 15 MG | 20% | +6.1% |
Medicare hospital outpatient (OPPS)
No authoritative public data was located for this field.
Washington Apple Health · professional claims
Not on HCA's professional administered drug fee schedule.
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
No CMS NDC–HCPCS crosswalk rows were located. CMS notes its crosswalks are not a comprehensive list of all NDCs.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 70121-1630-01 | TepadinaAMNEAL PHARMACEUTICALS, LLC | 1 × 1 | 1 | 1 | ASP | Q2 2025Not in Q4 2026 file | ListedTepadina |
| 70121-1631-01 | TepadinaAMNEAL PHARMACEUTICALS, LLC | 1 × 1 | 7 | 7 | ASP | Q2 2025Not in Q4 2026 file | ListedTepadina |
| 43598-0171-11 | ThiotepaDr. Reddy's Laboratories Inc. | 1 × 1 | 7 | 7 | ASP | Q2 2023 – Q2 2025Not in Q4 2026 file | ListedThiotepa |
| 43598-0650-11 | ThiotepaDr. Reddy's Laboratories Inc. | 1 × 1 | 1 | 1 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedThiotepa |
| 65219-0029-20 | ThiotepaFreseniUS Kabi USA, LLC | 1 × 1 | 7 | 7 | ASP | Q1 2023 – Q2 2025Not in Q4 2026 file | ListedThiotepa |
| 00143-9309-01 | ThiotepaHikma Pharmaceuticals USA Inc. | 1 × 1 | 1 | 1 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedThiotepa |
| 00143-9565-01 | ThiotepaHikma Pharmaceuticals USA Inc. | 1 × 1 | 1 | 1 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedThiotepa |
| 00143-9292-01 | ThiotepaHIKMA PHARMACEUTICALS USA INC. | 1 × 1 | 7 | 7 | ASP | Q1 2025 – Q2 2025Not in Q4 2026 file | ListedThiotepa |
| 71288-0156-05 | ThiotepaMeitheal Pharmaceuticals Inc. | 1 × 1 | 1 | 1 | ASP | Q3 2024 – Q2 2025Not in Q4 2026 file | ListedThiotepa |
| 71288-0157-10 | ThiotepaMeitheal Pharmaceuticals Inc. | 1 × 1 | 7 | 7 | ASP | Q3 2024 – Q2 2025Not in Q4 2026 file | ListedThiotepa |
| 72205-0045-01 | ThiotepaNovadoz Pharmaceuticals LLC | 1 × 1 | 1 | 1 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedThiotepa |
| 72205-0046-01 | ThiotepaNovadoz Pharmaceuticals LLC | 1 × 1 | 7 | 7 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedThiotepa |
| 25021-0246-02 | ThiotepaSagent Pharmaceuticals | 1 × 1 | 1 | 1 | ASP | Q1 2021 – Q2 2025Not in Q4 2026 file | ListedThiotepa |
| 54879-0014-13 | ThiotepaSTI PHARMA, LLC | 1 × 1 | 1 | 1 | ASP | Q2 2021 – Q4 2024Not in Q4 2026 file | Excluded listingThiotepa |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q3 2025 | Termination date set | D — Discontinued | Termination date Jun 30, 2025 |
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 1984 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| — |
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $209.016 | 15 MG | 20% | −8.0% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $227.255 | 15 MG | 20% | −0.5% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $228.364 | 15 MG | 20% | −9.1% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $251.205 | 15 MG | 20% | −3.5% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $260.251 | 15 MG | 20% | +0.3% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $259.563 | 15 MG | 20% | −12.7% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $297.263 | 15 MG | 20% | −6.6% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $318.169 | 15 MG | — | +6.4% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $299.066 | 15 MG | — | +0.3% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $298.191 | 15 MG | — | −2.8% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $306.843 | 15 MG | — | +0.5% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $305.449 | 15 MG | — | −0.1% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $305.844 | 15 MG | — | −32.6% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $453.460 | 15 MG | — | −9.3% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $499.788 | 15 MG | — | +9.9% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $454.817 | 15 MG | — | — | — |
|---|